European Group

Highlights - Opinion on Democracy in the Digital Age - Committee on Civil Liberties, Justice and Home Affairs

Retrieved on: 
Thursday, June 22, 2023
Commission, Digital, Democracy, Ethics, EGE, Information Age, European Group, Opinion, Science

Opinion on Democracy in the Digital Age

Key Points: 
  • Opinion on Democracy in the Digital Age
    22-06-2023 - 15:20
    European Group on Ethics in Science and New Technologies (EGE) handed over its Opinion on Democracy in the Digital Age to Commission Vice-President Dubravka Šuica.
  • Requested by President von der Leyen, the Opinion will guide the Commission in its efforts to address challenges to democracy and to foster it.
  • In their opinion, the EGE warns that democracy can quickly become an empty shell if it is not underpinned by fundamental rights and the values it seeks to protect and promote.

EBMI INKED MOA WITH SFIO TO BUILD A WORLD-CLASSS INTEGRATIVE CARE FACILITY IN PALAWAN, PHILIPPINES

Retrieved on: 
Monday, April 17, 2023
EW Group, Pictou County Wellness Centre, Partnership, Therapy, Research, Multimedia, Alternative medicine, European Technology Platform on Smart Systems Integration, Cosmeceutical, European Group, Mazumdar Shaw Medical Centre, Hospital, Ecosystem, Mall of America, SFIO, Starfleet, Airline, Pharmaceutical industry

The MoA was signed Prof. Dato' Sri Mike Chan, Chairman of EW Group and Jefferson D. Lacson, Founder of SFIO.

Key Points: 
  • The MoA was signed Prof. Dato' Sri Mike Chan, Chairman of EW Group and Jefferson D. Lacson, Founder of SFIO.
  • Through this partnership, both parties will develop and operate MORAYA's Integrative and Holistic Medicine facility, an eight-hectare eco-luxury community project, soon in Puerto Princesa, Palawan.
  • This project will provide a luxuriant and healthy-environment to the community mindfully designed to take holistic care of its residents.
  • The facility will be operated by using the EW Biological Regenerative systems and protocols, as well as treatment solutions and products developed by EW Group.

EBMI INKED MOA WITH SFIO TO BUILD A WORLD-CLASSS INTEGRATIVE CARE FACILITY IN PALAWAN, PHILIPPINES

Retrieved on: 
Monday, April 17, 2023
EW Group, Pictou County Wellness Centre, Partnership, Therapy, Research, Alternative medicine, European Technology Platform on Smart Systems Integration, Cosmeceutical, European Group, Mazumdar Shaw Medical Centre, Hospital, Ecosystem, Mall of America, SFIO, Starfleet, Airline, Pharmaceutical industry

MANILA, Philippines, April 17, 2023 /PRNewswire/ -- European Biological Medicine Inc., a subsidiary of European Wellness Biomedical Group (EW Group) has inked a Memorandum of Agreement (MoA) with Starfleet Innotech, Inc. (SFIO) to build a world-class integrative care facility in Palawan, Philippines under the MORAYA project, a real estate development company building wellness-oriented communities.

Key Points: 
  • MANILA, Philippines, April 17, 2023 /PRNewswire/ -- European Biological Medicine Inc., a subsidiary of European Wellness Biomedical Group (EW Group) has inked a Memorandum of Agreement (MoA) with Starfleet Innotech, Inc. (SFIO) to build a world-class integrative care facility in Palawan, Philippines under the MORAYA project, a real estate development company building wellness-oriented communities.
  • The MoA was signed Prof. Dato' Sri Mike Chan, Chairman of EW Group and Jefferson D. Lacson, Founder of SFIO.
  • Through this partnership, both parties will develop and operate MORAYA's Integrative and Holistic Medicine facility, an eight-hectare eco-luxury community project, soon in Puerto Princesa, Palawan.
  • This project will provide a luxuriant and healthy-environment to the community mindfully designed to take holistic care of its residents.

Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)

Retrieved on: 
Wednesday, November 16, 2022
Health, Clinical Trials, Research, Science, Pharmaceutical, Optical, Biotechnology, Inflammatory bowel disease, Clinical trial, Friends, Diplopia, Cell, TED, Menstrual disorder, Headache, Autoantibody, Safety, Disease, Hair, Huber loss, Breathe Me, Fibroblast, European Group, Week, Partnership, PMDA, Science, Research, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Hyperglycemia, Pain, Grit, COVID-19, Health, Hope, Diarrhea, Incidence, Patient, FDA, Trial of the century, Blood pressure, Pressure, Autoimmunity, Spasm, Swelling, Medicines and Healthcare products Regulatory Agency, Cover My Eyes (Pain and Heaven), Red, Graves' ophthalmopathy, Diabetes, Food, Fatigue, Courage, Tachycardia, Medicine, Myalgia, OPTIC, Inflammation, Nausea, Exophthalmos, Family, IBD, Pharmaceutical industry, Silviculture, Medical device, Medical imaging, Birth control, Dysgeusia

With this trial, we hope to explore the role that TEPEZZA could have for Japanese patients struggling with active Thyroid Eye Disease.

Key Points: 
  • With this trial, we hope to explore the role that TEPEZZA could have for Japanese patients struggling with active Thyroid Eye Disease.
  • The trial methodology is based on the OPTIC Phase 3 trial conducted in the United States and Europe.
  • We are so grateful for the participation and partnership of those living with Thyroid Eye Disease in Japan and our principal investigators, said Elizabeth H.Z.
  • The need for a non-surgical, non-steroidal treatment option for Thyroid Eye Disease in Japan is significant.

Horizon Therapeutics plc to Present New Data on TEPEZZA® (teprotumumab-trbw) and Thyroid Eye Disease (TED) at the American Thyroid Association (ATA) Annual Meeting

Retrieved on: 
Thursday, October 13, 2022
Biotechnology, Pharmaceutical, Optical, General Health, Health, FDA, Clinical Trials, Other Health, Pressure, Physician, LinkedIn, Spasm, Fibroblast, Breathe Me, Disease, Medicine, Diabetes, Nausea, Fatigue, Menstrual disorder, Graves' ophthalmopathy, Science, TED, Inflammatory bowel disease, Myalgia, FACP, Patient, Diarrhea, Courage, Tachycardia, Research, Twitter, Instagram, Cell, Blood pressure, Severe cognitive impairment, Hair, Nasdaq, Red, Grit, Hyperglycemia, Autoantibody, ATA, Headache, Swelling, Pain, Incidence, IBD, European Group, Lists of World Heritage Sites, Autoimmunity, Inflammation, Health, FDA, Exophthalmos, Huber loss, American Thyroid Association, Pharmaceutical industry, Vaccine, Medical device, Medical imaging, Birth control, Facebook, Dysgeusia

Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data will be presented at the 91st Annual Meeting of the American Thyroid Association ( ATA 2022 ) in Montreal, October 19-23.

Key Points: 
  • Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data will be presented at the 91st Annual Meeting of the American Thyroid Association ( ATA 2022 ) in Montreal, October 19-23.
  • We look forward to bringing these important data to the forefront to help physicians better understand the condition for their patients.
  • Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA.
  • Preexisting Inflammatory Bowel Disease: TEPEZZA may cause an exacerbation of preexisting inflammatory bowel disease (IBD).

New Data Reveal Molecular Drivers of Thyroid Eye Disease (TED) May Remain Activated In Patients with Low Clinical Activity Score (CAS)

Retrieved on: 
Sunday, October 2, 2022
Other Health, Health, Pharmaceutical, Optical, Clinical Trials, American Academy, Autoantibody, Health, Quality of life, Pressure, Jules Stein Eye Institute, Physician, Nasdaq, Anxiety, Research, Inflammation, Therapy, Disease, CAS, Exophthalmos, Lists of World Heritage Sites, FACP, Genome, UCLA, Pain, Grit, Science, Autoimmunity, American Academy of Ophthalmology, Veni, vidi, vici, Courage, ECM, Fibroblast, European Group, Risk, Graves' ophthalmopathy, TED, Instagram, Severe cognitive impairment, University of California, AAO, Twitter, LinkedIn, Â, Cell, Extracellular matrix, Red, RNA, University, Swelling, Pharmaceutical industry, Medical device, Vaccine, Hospital, Patient, Ophthalmology, Facebook

Though high CAS patients are often distinguished by activation of immune system pathways, which remain largely unaffected in low CAS patients, IGF-1 and its related pathways were found to be upregulated in both stages of disease.

Key Points: 
  • Though high CAS patients are often distinguished by activation of immune system pathways, which remain largely unaffected in low CAS patients, IGF-1 and its related pathways were found to be upregulated in both stages of disease.
  • We are committed to pioneering research like this to better understand drivers of the evolution of this disease in order to better support patients living with Thyroid Eye Disease across the course of their lifetimes.
  • Whole Genome Transcriptome Comparison of Acute and Chronic Thyroid Eye Disease: Emergence of a Molecular Signature.
  • Inflammatory and non-inflammatory thyroid eye disease: comparison of disease signs, symptoms and quality of life in US patients.

Horizon Therapeutics plc Completes Enrollment for Phase 4 Trial of TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)

Retrieved on: 
Thursday, September 29, 2022
Other Health, Health, Pharmaceutical, Optical, Clinical Trials, Safety, Autoantibody, Diabetes, Inflammatory bowel disease, Health, Pressure, Patient, Hair, Clinical trial, Nasdaq, Research, Menstrual disorder, Inflammation, Disease, Headache, Diplopia, CAS, Exophthalmos, Lists of World Heritage Sites, COVID-19, Blood pressure, Food, Tachycardia, Diarrhea, Orbital, Hyperglycemia, Pain, Grit, Science, Adult, Autoimmunity, Medicine, Nausea, SEC, Courage, Fibroblast, European Group, FDA, Graves' ophthalmopathy, Week, Partnership, TED, Instagram, Cedars-Sinai Medical Center, Fatigue, Incidence, Huber loss, Twitter, Spasm, LinkedIn, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cell, Red, Clinical, IBD, Myalgia, Swelling, Breathe Me, Pharmaceutical industry, Medical imaging, Vaccine, Medical device, Birth control, Dysgeusia, Facebook

Horizon Therapeutics plc (Nasdaq: HZNP) announced that it has completed enrollment of its Phase 4 clinical trial ( NCT04583735 ) evaluating TEPEZZA for the treatment of Thyroid Eye Disease (TED) in patients with a low Clinical Activity Score (CAS), also known as the TEPEZZA Chronic TED trial.

Key Points: 
  • Horizon Therapeutics plc (Nasdaq: HZNP) announced that it has completed enrollment of its Phase 4 clinical trial ( NCT04583735 ) evaluating TEPEZZA for the treatment of Thyroid Eye Disease (TED) in patients with a low Clinical Activity Score (CAS), also known as the TEPEZZA Chronic TED trial.
  • TEPEZZA was approved by the U.S. Food and Drug Administration (FDA) in January 2020 as the first and only medicine for Thyroid Eye Disease.
  • The TEPEZZA pivotal trial data showed significant improvement in some of the most debilitating symptoms of TED in people with more inflammatory disease.
  • We frequently hear people with Thyroid Eye Disease stress how the painful, potentially vision-threatening symptoms continue throughout the patient journey.

Horizon Therapeutics plc to Highlight Data and Education on Thyroid Eye Disease (TED) at the Endocrine Society (ENDO) 2022 Annual Conference

Retrieved on: 
Thursday, June 2, 2022
Health, Diabetes, Managed Care, General Health, Clinical Trials, Pharmaceutical, Optical, ENDO, Atlantic Station, Conference, Insomnia, National Track and Field Hall of Fame, Autoantibody, 2013 British National Track Championships, Weight loss, Inflammation, Irritation, Gold, Courage, Swelling, Convention, Endocrine system, Blood, Graves' ophthalmopathy, Diagnosis, Autoimmunity, National Primate Research Exhibition Hall, American Association of Clinical Endocrinologists, Patient, Career, Communications center, Cell, Translation, Exophthalmos, Fibroblast, University, Dry, Michigan Medicine, Teprotumumab, Gail Devers, Science, Health, Education, Fatigue, Strabismus, LinkedIn, TED, NorthShore University HealthSystem, Disease, Nasdaq, Lists of World Heritage Sites, Division, Twitter, Diplopia, Cover My Eyes (Pain and Heaven), Instagram, European Group, Pharmaceutical industry, Veterinary medicine, Olympian, Endocrinology, Facebook

ET in ENDOExpo Theater 1, titled Evolution of Thyroid Eye Disease (TED) Treatment With Teprotumumab: Translating Bench to Bedside with Terry J. Smith, M.D., Michigan Medicine Eye Plastic, Facial Cosmetic & Orbital Surgery, Kellogg Eye Center, University of Michigan Medical School.

Key Points: 
  • ET in ENDOExpo Theater 1, titled Evolution of Thyroid Eye Disease (TED) Treatment With Teprotumumab: Translating Bench to Bedside with Terry J. Smith, M.D., Michigan Medicine Eye Plastic, Facial Cosmetic & Orbital Surgery, Kellogg Eye Center, University of Michigan Medical School.
  • The event, Achieving Gold in the Co-Management of Thyroid Eye Disease (TED), will be held in The Career and Communications Center in the Exhibit Hall on Saturday, June 11 at 11 a.m.
  • Gail will also be sharing her story between 11 a.m. and 4 p.m.
  • After a harrowing two-and-a-half-year quest for answers, she was diagnosed with Graves disease in 1990, just two years before winning her first Olympic gold medal.

Horizon Therapeutics plc Launches Letter-Writing Campaign to Empower Those Living with Thyroid Eye Disease (TED) to Confront the Condition Head On

Retrieved on: 
Wednesday, May 11, 2022
Mental Health, Health, General Health, Pharmaceutical, Optical, Biotechnology, Lazarus, The Quality of Life Assessment of Growth Hormone Deficiency in Adults Measure, Exophthalmos, Lists of World Heritage Sites, Instagram, Twitter, Nasdaq, Fibroblast, Autoimmunity, Courage, Red, Depression, Grave, Thyroid disease, Hypothyroidism, Patient, Mental Health Awareness Month, TED, Letter, Severe cognitive impairment, Family, Hyperthyroidism, Anxiety, Cell, Epidemiology, Television, Health, Conditional sentence, Quality of life, LinkedIn, Graves' ophthalmopathy, Disease, Friends, Science, Autoantibody, European Group, Diplopia, Inflammation, Walking, Strabismus, TED (conference), Paced Auditory Serial Addition Test, American, Risk, Multimedia, Pharmaceutical industry, Health insurance, Vaccine, Silviculture, Atlantic Ocean, Facebook, The New York Times

Living with a rare or chronic disease is a very personal experience that can sometimes feel isolating and overwhelming, said Gottlieb.

Key Points: 
  • Living with a rare or chronic disease is a very personal experience that can sometimes feel isolating and overwhelming, said Gottlieb.
  • My relationship with TED hasnt been easy, but because of what Ive been through, I take pride in everything Ive accomplished.
  • It is important to monitor eye symptoms and take weekly pictures to capture any changes in appearance.
  • Cockerham K, Stuertz N, Padnick-Silver L. Quality of Life Assessment of Chronic Thyroid Eye Disease (TED) Patients in the United States.

American Society of Clinical Oncology (ASCO) Clinical Practice Guideline Now Includes Breast Cancer Index™ to Guide Decisions about Extended Endocrine Therapy

Retrieved on: 
Monday, April 25, 2022
Women, Genetics, Clinical Trials, Other Health, Biotechnology, Managed Care, General Health, Consumer, Health, Oncology, American Joint Committee on Cancer, ASCO, Society, Breast cancer, Recurrence, Osteoporosis, CAP, Woman, European Group, British Columbia Basic Income Expert Panel Report, LDT, Oncology, US Foods, MD, Food, American Society of Clinical Oncology, Bone, Patient, Financial toxicity, Science, Literature, BCI, Nasdaq, American Journal of Clinical Oncology, Journal, ESMO, European Society for Medical Oncology, Safety, Guideline, HOLX, Physician, Decision-making, Quality of life, Disease, Risk, Health, HR, Side, National Disaster Management Authority (India), Medical imaging, Wood-plastic composite, Audit, Cancer, Hologic

Hologic, Inc. (Nasdaq: HOLX) announced today that the American Society of Clinical Oncology (ASCO) has published an update which expands the utility of Breast Cancer Index (BCI) within its Clinical Practice Guideline: Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer.

Key Points: 
  • Hologic, Inc. (Nasdaq: HOLX) announced today that the American Society of Clinical Oncology (ASCO) has published an update which expands the utility of Breast Cancer Index (BCI) within its Clinical Practice Guideline: Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer.
  • Breast Cancer Index is a molecular, gene expression-based test uniquely positioned to provide information to help physicians individualize treatment decisions for patients with early-stage, HR+ breast cancer.
  • Breast Cancer Index has guideline designation from the American Joint Committee on Cancer for cancer staging based on molecular profile.
  • Breast Cancer Index is intended for routine clinical use, and treatment decisions based on results are the responsibility of the physician.